The inhalation of drugs: Advantages and problems

Respiratory Care

Volumn 50, Issue 3, 2005, Pages 367-382

  Rau, Joseph L ^a,b  

^a GEORGIA STATE UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Aerosol; DPI; Dry powder inhaler; MDI; Metered dose inhaler; Nebulizer

Indexed keywords

ADRENALIN; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CICLESONIDE; CROMOGLYCATE DISODIUM; EPHEDRINE; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE; ISOPRENALINE; LEVALBUTEROL; ORCIPRENALINE; PENICILLIN G; SALBUTAMOL; SALBUTAMOL SULFATE; SALMETEROL; STRAMONIUM; TERBUTALINE; TIOTROPIUM BROMIDE; ZANAMIVIR; RESPIRATORY TRACT AGENT;

AEROSOL; ARTICLE; ASTHMA; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG USE; EVIDENCE BASED PRACTICE; HUMAN; INHALATION SPACER; INHALATIONAL DRUG ADMINISTRATION; ISOTOPE LABELING; MATHEMATICAL MODEL; MEDICAL NEBULIZER; METERED DOSE INHALER; PATIENT COMPLIANCE; POWDER INHALER; RESPIRATORY CARE; RESPIRATORY TRACT INFECTION; STANDARDIZATION; TACHYCARDIA; TREMOR; EQUIPMENT DESIGN; EVIDENCE BASED MEDICINE; HISTORY; INSTRUMENTATION; NEBULIZER; POWDER; RESPIRATORY TRACT DISEASE; UNITED STATES;

ADMINISTRATION, INHALATION; AEROSOLS; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; EVIDENCE-BASED MEDICINE; HISTORY, 20TH CENTURY; HUMANS; METERED DOSE INHALERS; NEBULIZERS AND VAPORIZERS; POWDERS; RESPIRATORY SYSTEM AGENTS; RESPIRATORY TRACT DISEASES; UNITED STATES;

EID: 21544471534     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Gandevia B. Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad Med J 1975;51(7 Suppl):13-20.
2. Anderson PJ. Delivery options and devices for aerosolized therapeutics. Chest 2001;120(3 Suppl):89S-93S.
3. Muers MF. Overview of nebuliser treatment. Thorax 1997;52 Suppl 2:S25-S30.
4. Camps PWL. A note on the inhalation treatment of asthma. Guy's Hosp Report 1929;79:496-498.
5. Benson RL, Perlman F. Clinical effects of epinephrine by inhalation: a survey. J Allergy 1948;19:129-140.
6. Barrett TE, Strom BL. Inhaled beta-adrenergic receptor agonists in asthma: more harm than good? Am J Respir Crit Care Med 1995; 151(2 Pt 1):574-577.
7. Bryson V, Sansome E, Laskin S. Aerosolization of chemotherapeutic substances. Lancet 1944;2:775-780.
8. Krasno LR, Rhoads PS. The inhalation of penicillin dust; its proper role in the management of respiratory infections. Amer Practitioner 1949;3:649-653.
9. Thiel CG. From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regulation. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery, 5th ed. Buffalo Grove, Illionois: Interpharm Press; 1996:115-123.
10. Bell JH, Hartley PS, Cox JS. Dry powder aerosols. I. A new powder inhalation device. J Pharm Sci 1971;60(10):1559-1563.
11. Fisons Corporation monograph. INTAL (cromolyn sodium - Fisons). Bedford, Massachusetts: Fisons Corporation; 1974.
12. Dolovich M. Spacer design II: Holding chambers and valves. Oral presentation at the International Symposium on Spacer Devices, Drug Information Association, Boston MA, 1995. Proceedings unpublished.
13. Coady TJ, Davies HJ, Barnes P. Evaluation of a breath actuated pressurized aerosol. Clin Allergy 1976;6(1):1-6.
14. Moren F. Drug deposition of pressurized inhalation aerosols. I. Influence of actuator tube design Int J Pharmacol 1978;1:205-212.
15. Newman SP, Pavia D, Moren F, Sheahan NF, Clarke SW. Deposition of pressurised aerosols in the human respiratory tract. Thorax 1981;36(1):52-55.
16. Newman SP, Moren F, Pavia D, Little F, Clarke SW. Deposition of pressurized suspension aerosols inhaled through extension devices. Am Rev Respir Dis 1981;124(3):317-320.
17. Tobin MJ, Jenouri G, Danta I, Kim C, Watson H, Sackner MA. Response to bronchodilator drug administration by a new reservoir aerosol delivery system and a review of other auxiliary delivery systems. Am Rev Respir Dis 1982;126(4):670-675.
18. Dolovich M, Ruffin R, Corr D, Newhouse MT. Clinical evaluation of a simple demand inhalation MDI aerosol delivery device. Chest 1983;84(1):36-41.
19. Pierce AK, Saltzman HA. Final reports-summaries and recommendations. Aerosol therapy. Am Rev Respir Dis 1974;110(6 Suppl): 7-9.
20. Brain J. Aerosol and humidity therapy. Am Rev Respir Dis 1980; 122(5 Pt 2):17-21.
21. Ziment I. Why are they saying bad things about IPPB? Respir Care 1973;18(6):677-689.
22. Newman SP, Woodman G, Clarke SW, Sackner MA. Effect of InspirEase on the deposition of metered-dose aerosols in the human respiratory tract. Chest 1986;89(4):551-556.
23. Lewis RA, Fleming JS. Fractional deposition from a jet nebulizer: how it differs from a metered dose inhaler. Br J Dis Chest 1985; 79(4):361-367.
24. Newman SP, Hollingworth A, Clark AR. Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int J Pharm 1994;102:127-132.
25. Dulfano MJ, Glass P. The bronchodilator effects of terbutaline: route of administration and patterns of response. Ann Allergy 1976;37(5): 357-366.
26. Grimwood K, Johnson-Barrett JJ, Taylor B. Salbutamol: tablets, inhalational powder, or nebuliser? Br Med J (Clin Res Ed) 1981; 282(6258):105-106.
27. Thiringer G, Svedmyr N. Comparison of infused and inhaled terbutaline in patients with asthma. Scand J Respir Dis 1976;57(1):17-24.
28. Mestitz H, Copland JM, McDonald CF. Comparison of outpatient nebulized vs metered dose inhaler terbutaline in chronic airflow obstruction. Chest 1989;96(6):1237-1240.
29. Zainudin BM, Biddiscombe M, Tolfree SE, Short M, Spiro SG. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurized metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 1990;45(6):469-473.
30. Raimondi AC, Schottlender J, Lombardi D, Molfino NA. Treatment of acute severe asthma with inhaled albuterol delivered via jet nebulizer, metered dose inhaler with spacer, or dry powder. Chest 1997; 112(1):24-28.
31. Partridge MR. Metered-dose inhalers and CFCs: what respiratory physicians need to know. Respir Med 1994;88(9):645-647.
32. Balmes JR. Propellant gases in metered dose inhalers: their impact on the global environment. Respir Care 1991;36(9):1037-1044.
33. Tashkin D. New devices for asthma. J Allergy Clin Immunol 1998; 101(2 Pt 2):S409-S416.
34. Kleerup EC, Tashkin DP, Cline AC, Ekholm BP. Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma. Chest 1996;109(3): 702-707.
35. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998;12(6):1346-1353.
36. Rau JL. Respiratory care pharmacology, 6th ed. St Louis: Mosby-Year Book;2002:53.
37. Bousquet J, Cantini L. Clinical studies in asthmatics with a new non-extra fine HFA formulation of beclometasone dipropionate (BDP Modulite). Respir Med 2002;96 Suppl D:S17-S27.
38. Liquid nebulization: emerging technologies, part I. Respir Care 2002; 47(11):1256-1336.
39. Liquid nebulization: emerging technologies, part II: Respir Care 2002; 47(12):1392-1476
40. Rau JL. Design principles of liquid nebulization devices currently in use. Respir Care 2002;47(11):1257-1275; discussion 1275-1278.
41. Dennis JH. A review of issues relating to nebulizer standards. J Aerosol Med 1998; 11 Suppl 1:S73-S79.
42. O'Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax 1997;52(Suppl 2):S31-S44.
43. Rau JL, Ari A, Restrepo RD. Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric. Respir Care 2004;49(2):174-179.
44. Denyer J. Adaptive aerosol delivery in practice. Eur Respir Rev 1997;7:388-389.
45. Nikander K. Adaptive aerosol delivery: the principles. Eur Respir Rev 1997;7:385-387.
46. Dolovich M. New propellant-free technologies under investigation. J Aerosol Med 1999;12 Suppl 1:S9-S17.
47. Newman SP. Use of gamma scintigraphy to evaluate the performance of new inhalers. J Aerosol Med 1999;12 Suppl 1:S25-S31.
48. Geller DE. New liquid aerosol generation devices: systems that force pressurized liquids through nozzles. Respir Care 2002;47(12):1392-1404.
49. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002;96(5):293-304.
50. Nelson H, Kemp JP, Bieler S, Vaughan LM, Hill MR. Comparative efficacy and safety of albuterol sulfate Spiros inhaler and albuterol metered-dose inhaler in asthma. Chest 1999;115(2):329-335.
51. Warren S, Taylor G, Godfrey C, Coté G, Hill M. Gamma scintigraphic evaluation of beclomethasone dipropionate (BDP) from the Spiros dry powder inhaler (abstract). J Aerosol Med 1999;12(3):117.
52. Hirst PH, Newman SR, Clark DA, Hertog MG. Lung deposition of budesonide from the novel dry powder inhaler Airmax. Respir Med 2002;96(6):389-396.
53. Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest 1998; 113(4):957-963.
54. Milgrom H, Skoner DP, Bensch G, Kim KT, Claus R, Baumgartner RA. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001;108(6):938-945.
55. Hanania NA, Wittman, Kesten S, Chapman KR. Medical personnel's knowledge of and ability to use inhaling devices. Metered dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest 1994;105(1):111-116.